Elad Kedar, CEO, Orasis discusses CSF-1, the company's corrective eye drop being developed for the treatment of presbyopia as an alternative to reading glasses.  Presbyopia, the inability to focus on near objects, is common after the age of 40 and affects more than 1.8 billion people worldwide.  While glasses have been used for hundreds of years to correct vision, ophthalmologists are excited about these innovative eye drops that will change eye care. Orasis-Pharma.com